Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / DXP-4273-2022
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorŞahin, Taha Koray
dc.contributor.authorYıldırım, Hasan Çağrı
dc.contributor.authorÇeşmeci, Engin
dc.contributor.authorGülbahçe İncesu, Fatıma Gül
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2021-11-10T13:34:46Z
dc.date.available2021-11-10T13:34:46Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: We compared the new outpatient clinic referrals during the first 10 months of the COVID-19 pandemic with the year before. Methods: We compared baseline characteristics of the 2208 new referrals in 2020 (n=922) and 2019 (n=1286) with ?2 and Mann-Whitney U tests and calculated ORs with binary logistic regression. To evaluate the expected changes in the cancer survival secondary to stage migration, we used the 5-year survival data of Survival, Epidemiology and End Results (SEER) Program 2010-2016. Results: The percentage of patients with inoperable or metastatic disease was significantly increased during the pandemic (49.8% vs 39%, OR: 1.553, 95% CI: 1.309 to 1.843, p<0.001). We observed a significant decrease in the percentage of patients diagnosed via the screening methods (18.8% vs 28.7%, OR: 1.698, 95% CI: 1.240 to 2.325, p=0.001). The 90-day mortality after the cancer diagnosis was significantly higher during the pandemic (10.5% vs 6.6%, OR: 1.661, 95% CI: 1.225 to 2.252, p=0.001). Due to the increased advanced-stage disease rate at first referral, significant decreases in 5-year survival rates were expected for breast cancer (-8.9%), colorectal cancer (-11.1%), cervix cancer (-10.3%) and melanoma (-7%). Conclusion: We think that collaborative efforts are paramount to prevent the pandemic of late cancer diagnoses and ensure patient safety during the pandemic.en_US
dc.identifier.citationGuven, D. C., Sahin, T. K., Yildirim, H. C., Cesmeci, E., Incesu, F., Tahillioglu, Y., Ucgul, E., Aksun, M. S., Gurbuz, S. C., Aktepe, O. H., Arik, Z., Dizdar, O., Yalcin, S., Aksoy, S., Kilickap, S., & Kertmen, N. (2021). Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality. BMJ supportive & palliative care, bmjspcare-2021-003301. Advance online publication. https://doi.org/10.1136/bmjspcare-2021-003301en_US
dc.identifier.doi10.1136/bmjspcare-2021-003301en_US
dc.identifier.pmid34711656en_US
dc.identifier.urihttps://doi.org/10.1136/bmjspcare-2021-003301
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2217
dc.identifier.wosWOS:000723328900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherBMJen_US
dc.relation.ispartofBMJ Support Palliat Care .en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectCanceren_US
dc.titleNewly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortalityen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
bmjspcare-2021-003301.full.pdf
Boyut:
567.56 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu